Q-omics provides the consensus-scored MIR595 profile across patient tissues and cancer cell-line models. MIR595 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR595 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, MIR595 RNA expression shows 7,902 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, STAD, and ESCA as cancer lineages where MIR595 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR595 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR595 survival associations across molecular data types. MIR595 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR595 RNA expression–survival associations across cancer types. High MIR595 expression shows unfavorable associations in KIRC, UCEC, BLCA, LUAD, ESCA and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR595 RNA expression.
This table summarizes MIR595 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR595. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR595 shows higher tumor expression in STAD and PRAD. The STAD box plot shows higher MIR595 RNA expression in tumor versus normal tissue (log2 FC = +0.253, t-test p = .019).
This table shows molecular features associated with MIR595 in patient tissues and cancer cell lines. In patient samples, MIR595 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
